A subgroup analysis in the trial above revealed the effectiveness of epigenetic silencing of the O6-methylguanine-DNA methyltransferase (MGMT) gene via promoter methylation, with longer survival, in patients with primary GBM. Here, MGMT is linked to glioblastoma.